PYC Therapeutics Limited (ASX: PYC) - Share Price

- Current share price for PYC : $1.535

PYC Therapeutics (PYC), an ASX-listed company, is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class.

PYC General Information ⁺

ASX Code	PYC
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	1,509
PYC Share Price	$1.535
Day High	$1.535
Day Low	$1.500
Last Close	$1.535
PYC Share Price Movement	- ( No change )

Prices as at 16:36, 26 Jun 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

PYC Therapeutics Limited (PYC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from PYC Therapeutics Limited (PYC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

PYC Therapeutics Limited (PYC) price-sensitive announcements

PYC - PKD - Initiation of Multiple Dose Clinical Trial

PYC Therapeutics Limited has initiated a Phase 1b Multiple Ascending Dose (MAD) clinical t

PYC Therapeutics Limited (PYC)
7 May 2026 | 9:03 AM

PYC - Presentation of Ophthalmology Clinical Trial Data at ARVO

PYC Therapeutics Limited, an Australian biotechnology company, announced the presentation

PYC Therapeutics Limited (PYC)
4 May 2026 | 9:14 AM

PYC - Quarterly Activities/Appendix 4C Cash Flow Report

PYC Therapeutics Limited is advancing its clinical trials for Polycystic Kidney Disease an

PYC Therapeutics Limited (PYC)
28 Apr 2026 | 9:12 AM

PYC - ADOA Program - SRC Approve Progression to Multi-Dose Study

PYC Therapeutics Limited, a precision medicine company based in Perth, Australia, announce

PYC Therapeutics Limited (PYC)
15 Apr 2026 | 10:53 AM

PYC Therapeutics Limited (PYC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	Notification of cessation of securities - PYC	18 Jun 2026 8:26AM	$1.335	$1.535	risen by 14.98%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	Becoming a substantial holder	16 Jun 2026 4:29PM	$1.270	$1.535	risen by 20.87%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	Company Secretary Appointment/Resignation	15 Jun 2026 3:01PM	$1.225	$1.535	risen by 25.31%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	Notice of General Meeting/Proxy Form	12 Jun 2026 3:55PM	$1.215	$1.535	risen by 26.34%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	Change to CEO remuneration	26 May 2026 7:23PM	$1.380	$1.535	risen by 11.23%
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID	Health Care	$1,510	2026 Q2 Investor Webinar Presentation	22 May 2026 9:17AM	$1.305	$1.535	risen by 17.62%

PYC Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$11.00	31.00%	0.00%	0.0%
2026F	C2	-$8.40	-14.50%	0.00%	0.0%
2025A	-$51.01	-$9.80	5.50%	0.00%	0.0%

PYC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
CSL Limited (CSL)	$55,070M	0.1108	-0.1307	0.0166	12.3304	14.1849	13.9537	3.88%	3.13%	3.26%
Clinuvel Pharmaceuticals Limited (CUV)	$514M	0.0287	0.0233	0.0942	14.2061	13.8832	12.6881	0.49%	0.71%	1.15%
Mesoblast Limited (MSB)	$2,887M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,515M	0.0548	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,338M	-1.3893	0.0000	-0.1306	0.0000	293.4701	337.5536	0.00%	0.00%	0.00%

PYC Directors

Name	Position	Start Date
Dr Rohan Hockings	Chief Executive Officer, Managing Director	30 Nov 2018
Mr Peter John Coleman	Non-Executive Chairman, Non-Executive Director	18 Nov 2025
Professor Ian Jeffrey Constable	Non-Executive Director	21 Sep 2025

PYC Therapeutics Limited (PYC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
24 Mar 2026	HOCKINGS, Rohan	Buy	Direct Shares	82,550	$1.210	$99,883.000
6 Mar 2026	HOCKINGS, Rohan	Issued	Direct Shares	80,010	$1.500	$120,015.000
6 Mar 2026	CONSTABLE, Ian	Issued	Indirect Shares	123,000	$1.500	$184,500.000

See all changes in directors' interest & trades for PYC Therapeutics Limited (PYC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PYC Management

Name	Position
Jonathan Riley	Joint Company Secretary
Stephen Ledger	Joint Company Secretary

PYC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in PYC Therapeutics Limited (PYC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
186,726,741 (32.01%)	Australian Land Pty Ltd

PYC Calendar of Events

Date	Event
22 February 2027	Report (Interim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us